V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220014871 | 220015032 | null | 67.5 | Curative (C) | 2015-07-16 | 2015-07-16 | FIGARO TRIAL | N | N | 220035982 | CAPECITABINE |
| 220014872 | 220009487 | 1.65 | 84.4 | Palliative (P) | 2015-12-31 | 2015-12-31 | Cisplatin | 02 | N | 220036006 | ECF |
| 220014873 | 220009488 | 1.77 | 71.8 | Palliative (P) | 2014-03-23 | 2014-04-01 | Midostaurin | N | N | 220036006 | UKALL 2011 |
| 220014874 | 220009489 | 1.57 | 87.2 | Curative (C) | 2015-03-16 | 2015-03-16 | Folfirinox | N | N | 220036013 | EOX |
| 220014875 | 220009489 | 1.49 | 48.7 | Palliative (P) | 2015-07-18 | 2015-07-31 | Eribulin | 2 | N | 220036013 | CYTARABINE + MITOXANTRONE |
| 220014876 | 220009490 | 1.67 | 80.7 | null | 2014-10-21 | 2014-10-21 | Pazopanib | N | N | 220036034 | NIVOLUMAB |
| 220014877 | 220009494 | 1.73 | 84.5 | Palliative (P) | 2014-09-26 | 2014-10-12 | CARBOPLATIN | 2 | N | 220036036 | EOX |
| 220014878 | 220015037 | null | 0 | Palliative (P) | 2013-11-22 | 2013-12-12 | Gemcitabine 1000mg/m2 D1 8 15 | 2 | N | 220036041 | DOCETAXEL + GEMCITABINE |
| 220014879 | 220015037 | 1.62 | 78.4 | null | 2017-09-16 | 2017-09-24 | Mercaptopurine | 02 | N | 220036041 | RAVVA TRIAL |
| 220014880 | 220015037 | 1.56 | 0 | Palliative (P) | 2015-05-10 | 2015-05-10 | FLUOROURACIL + MITOMYCIN | 02 | N | 220036041 | CETUXIMAB + IRINOTECAN + MDG |
| 220014881 | 220009496 | 1.6 | null | Palliative (P) | 2017-01-11 | 2017-01-15 | TRASTUZUMAB | Y | N | 220036056 | CISPLATIN + ETOPOSIDE |
| 220014882 | 220009497 | 1.72 | 76.6 | Palliative (P) | 2015-10-21 | 2015-10-28 | CAPECITABINE + OXALIPLATIN | 2 | N | 220036057 | RALTITREXED |
| 220014883 | 220009497 | null | null | null | 2016-08-09 | 2016-08-21 | CISPLATIN + RT | N | N | 220036057 | MIDAC |
| 220014884 | 220009499 | 1.59 | null | null | 2014-06-25 | 2014-06-30 | BUSULFAN + CYCLO | 2 | N | 220036061 | IPILIMUMAB |
| 220014885 | 220009500 | 1.41 | 51.5 | Palliative (P) | 2014-10-28 | 2014-11-24 | Gemcitabine weekly | N | N | 220036062 | FCR |
| 220014886 | 220009501 | 1.96 | 118.5 | Palliative (P) | 2017-08-05 | 2017-08-19 | CAMELLIA Trial | N | N | 220036071 | DABRAFENIB + TRAMETINIB |
| 220014887 | 220009502 | 1.75 | null | Not known (9) | 2016-05-01 | 2016-05-01 | CISPLATIN + RT | N | N | 220036081 | IPILIMUMAB |
| 220014888 | 220009502 | 1.79 | 66 | Disease modification (D) | 2015-11-09 | 2015-12-03 | MidAC | 1 | N | 220036081 | ETOPOSIDE |
| 220014889 | 220009503 | 1.62 | 64.6 | Palliative (P) | 2014-01-01 | 2014-01-04 | Alemtuz+Cyclophos+Fludara Allo | 2 | N | 220036088 | MERCAPTOPURINE + METHOTREXATE |
| 220014892 | 220009505 | 1.67 | 85.1 | Disease modification (D) | 2014-03-23 | 2014-04-06 | RAVVA TRIAL | N | N | 220036098 | ERLOTINIB |
| 220014893 | 220009506 | null | 66.7 | Palliative (P) | 2016-03-29 | 2016-05-14 | Alemtuzumab+Busulfan+CyclophosphMUD | N | N | 220036098 | CETUXIMAB + IRINOTECAN + MDG |
| 220014896 | 220009508 | 1.84 | null | Curative (C) | 2015-03-27 | 2015-05-09 | Fluorouricil + Folonic Acid (MdG) | N | N | 220036121 | CAPECITABINE |
| 220014897 | 220009514 | null | null | Adjuvant (A) | 2013-10-23 | 2013-10-31 | Carboplatin AUC 2 - 5 | null | null | 220036144 | CYTARABINE + FLUDARABINE + IDARUBICIN |
| 220014899 | 220009518 | 1.84 | 79 | Palliative (P) | 2016-11-08 | 2016-11-15 | Busulfan Oral | 2 | N | 220036150 | GEMCITABINE |
| 220014900 | 220009520 | 1.56 | 78.6 | null | null | 2015-09-19 | Carboplatin AUC 2 - 5 | N | N | 220036156 | CAPECITABINE |
| 220014901 | 220009521 | null | null | Palliative (P) | 2013-08-14 | 2013-08-14 | FIGARO TRIAL | null | null | 220036162 | CVD |
| 220014902 | 220009521 | null | null | Palliative (P) | 2016-03-16 | 2016-04-27 | IBRUTINIB | 99 | N | 220036162 | CHOP |
| 220014904 | 220015049 | 1.61 | null | Disease modification (D) | 2015-05-08 | 2015-05-15 | IVE | N | N | 220036169 | CAPECITABINE + CARBOPLATIN |
| 220014905 | 220009523 | 1.64 | 48.8 | Curative (C) | 2014-07-26 | 2014-07-26 | Ipilimumab | 1 | N | 220036174 | SORAFENIB |
| 220014906 | 220015050 | 1.91 | 96 | Palliative (P) | 2017-12-01 | 2017-12-10 | Temozolomide 150mg/m2 | N | N | 220036180 | LIPOSOMAL CYTARABINE |
| 220014907 | 220019991 | null | null | Curative (C) | 2017-01-19 | 2017-01-19 | VIDE | N | null | 220036184 | CARBOPLATIN |
| 220014908 | 220019991 | 1.62 | 52.2 | Palliative (P) | 2013-12-17 | 2013-12-17 | CETUXIMAB | N | N | 220036184 | CAPECITABINE |
| 220014909 | 220019991 | 1.67 | 80.3 | Disease modification (D) | 2017-01-06 | 2017-01-06 | IGEV R | N | null | 220036184 | PAD |
| 220014910 | 220009524 | 1.83 | 84 | Palliative (P) | 2014-07-17 | 2014-07-17 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | 220036196 | MITOXANTRONE + TRETINOIN |
| 220014911 | 220015051 | null | null | Disease modification (D) | 2018-04-26 | 2018-04-27 | VINCRISTINE | N | null | 220036201 | DAUNORUBICIN |
| 220014912 | 220009525 | 1.55 | 0 | Not known (9) | 2015-07-31 | 2015-08-14 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | N | N | 220036202 | CETUXIMAB + RT |
| 220014914 | 220009528 | 1.58 | null | Not known (9) | 2014-08-10 | 2014-08-20 | Gemcitabine weekly | null | N | 220036215 | BORTEZOMIB |
| 220014915 | 220009530 | 2 | 68.6 | null | 2015-12-25 | 2015-12-25 | PEMBROLIZUMAB | 02 | N | 220036215 | TRASTUZUMAB |
| 220014916 | 220009531 | 1.67 | 54 | Palliative (P) | 2016-01-21 | 2016-01-27 | Liposomal Doxorubicin (Caelyx) | N | Y | 220036225 | ETOPOSIDE |
| 220014917 | 220009533 | 1.59 | 77.2 | Palliative (P) | 2017-08-30 | 2017-09-16 | Cisplatin | N | N | 220036225 | CARBOPLATIN |
| 220014918 | 220009535 | 1.82 | 69.1 | Disease modification (D) | 2015-03-15 | 2015-03-21 | Cisplatin 7 day | Y | N | 220036229 | CAP |
| 220014919 | 220009535 | 1.69 | 33.4 | Palliative (P) | 2014-12-08 | 2014-12-12 | Arsenic Trioxide (Induction Week) | N | null | 220036229 | FIGARO TRIAL |
| 220014920 | 220009536 | null | null | Palliative (P) | 2017-07-14 | 2017-07-14 | Alemtuzumab+Busulfan+CyclophosphMUD | N | null | 220036230 | FLUDARABINE |
| 220014921 | 220009538 | 1.7 | 81.9 | Palliative (P) | 2017-02-26 | 2017-03-03 | MACE | 02 | N | 220036240 | LI-1 TRIAL |
| 220014922 | 220015060 | 1.78 | 79 | Palliative (P) | 2015-03-23 | 2015-03-29 | EEF or EOF | 02 | N | 220036241 | BENDAMUSTINE + RITUXIMAB |
| 220014923 | 220009540 | 0 | 68.4 | Disease modification (D) | null | 2015-07-28 | CISPLATIN + METHOTREXATE + VINCRISTINE | N | N | 220036243 | BEP |
| 220014924 | 220009541 | 1.75 | 86.2 | Curative (C) | 2015-12-04 | 2015-12-04 | Packer Induction Vincristine + RT | N | N | 220036245 | CARBOPLATIN |
| 220014925 | 220009541 | null | 78.5 | Palliative (P) | 2018-08-20 | 2018-09-10 | Paclitaxel+Trastuzumab 21day Load | 02 | null | 220036245 | BORTEZOMIB |
| 220014926 | 220009542 | 1.69 | 94 | Palliative (P) | 2015-08-03 | 2015-08-03 | CHOP R - 21 days | N | N | 220036248 | MACE |
| 220014927 | 220009543 | null | null | Disease modification (D) | null | 2017-07-06 | Arsenic Trioxide (Induction Week) | null | null | 220036269 | CAPECITABINE |